Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.75.

Several research firms have recently issued reports on AUTL. Mizuho decreased their price objective on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Waverly Advisors LLC acquired a new stake in Autolus Therapeutics during the first quarter valued at approximately $37,000. Cetera Investment Advisers lifted its stake in Autolus Therapeutics by 2.7% during the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after purchasing an additional 29,324 shares during the last quarter. R Squared Ltd lifted its stake in Autolus Therapeutics by 48.4% during the first quarter. R Squared Ltd now owns 39,575 shares of the company’s stock valued at $55,000 after purchasing an additional 12,915 shares during the last quarter. SmartHarvest Portfolios LLC lifted its stake in Autolus Therapeutics by 177.0% during the first quarter. SmartHarvest Portfolios LLC now owns 59,185 shares of the company’s stock valued at $82,000 after purchasing an additional 37,820 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Autolus Therapeutics by 334.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 123,279 shares of the company’s stock valued at $245,000 after purchasing an additional 94,873 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.49 on Friday. The firm has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.55. The stock has a market capitalization of $396.58 million, a PE ratio of -1.37 and a beta of 2.02. Autolus Therapeutics has a 12-month low of $1.18 and a 12-month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The business had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. On average, analysts forecast that Autolus Therapeutics will post -0.96 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.